Sandbox:DAMI: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
== Overview ==


== Historical Perspective ==
== Classification ==
== Pathophysiology ==
== Causes ==
== Differentiating Gynecomastia from Other Diseases ==
== Epidemiology and Demographics ==
__NOTOC__
__NOTOC__


Line 48: Line 36:
* Disorders of sex development
* Disorders of sex development
* Familial prepubertal gynecomastia
* Familial prepubertal gynecomastia
=== Causes ===
== Screening ==
==Natural History, Complication and Prognosis==
== Diagnosis ==
== Treatment ==
== Case study ==
==References==
{{Reflist|2}}

Revision as of 16:24, 18 May 2017


Gynecomastia risk factors

Risk factors

The most potent risk factor in the development of gynecomastia is idiopathic often multifactorial.

Common Risk Factors

  • Idiopathic
  • Drugs (12765)
    • Spironolactone
    • Cimetidine
    • Recombinant Human Growth Hormone
    • Estrogens
    • Human Chorionic gonadotropin
    • Anti-androgens
    • Gonadotropin Releasing hormone (GNRH) agonists
    • 5-alpha reductase inhibitors
    • Ketoconazole
    • steroids
    • INH
    • Digoxin[1]
  • Cirrhosis
  • Starvation and Refeeding
  • Male hypogonadism
  • Testicular neoplasms
  • Hyperthyroidism
  • Chronic Kidney disease
  • Tumors

Less Common Risk Factors

  • Feminizing adrenal tumors
  • Ectopic hCG
  • Disorders of sex development
  • Familial prepubertal gynecomastia
  1. ↑ Braunstein GD (1993). "Gynecomastia". N Engl J Med. 328 (7): 490–5. doi:10.1056/NEJM199302183280708. PMID 8421478.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:DAMI&oldid=1311953"